skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation

Review

(1459) Views  (390) Full article downloads

Authors: Renee M Sullivan, Brian Olshansky

Published Date September 2010 Volume 2010:5 Pages 49 - 59
DOI: http://dx.doi.org/10.2147/CE.S7015

Renee M Sullivan, Brian Olshansky
Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA

Introduction: Dronedarone, a benzofuran derivative with a structure similar to amiodarone, has been developed as a potential therapy for patients with atrial fibrillation.
Aim: To review the published evidence regarding the efficacy and safety of dronedarone use in patients with atrial fibrillation.
Evidence review: Available evidence suggests that dronedarone 400 mg orally twice daily can lengthen the time to and decrease the overall recurrence of atrial fibrillation compared with placebo. Dronedarone may reduce risk of mortality and cardiovascular hospitalization. Patients with atrial fibrillation receiving dronedarone had improved ventricular rate control compared with patients receiving placebo. Dronedarone is associated with few serious adverse events except, notably, in patients with decompensated heart failure.
Place in therapy: Dronedarone may have a role in rate and rhythm control for patients with atrial fibrillation. Dronedarone can reduce unique, but potentially serious, end points in patients with atrial fibrillation. Despite this, the exact role of dronedarone in the management of patients with atrial fibrillation continues to emerge. It remains uncertain if dronedarone should be considered a primary treatment strategy for atrial fibrillation. Dronedarone should not be administered to patients with decompensated heart failure.
Conclusion: Dronedarone is a unique drug that may serve a key role to treat patients with atrial fibrillation.

Keywords: dronedarone, atrial fibrillation






Readers of this article also read:

Epidemiology of deep venous thrombosis during pregnancy and puerperium in Sudanese women
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells
Role of osteogenic protein-1/bone morphogenetic protein-7 in spinal fusion
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
Nanostructured delivery system for zinc phthalocyanine: preparation, characterization, and phototoxicity study against human lung adenocarcinoma A549 cells
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University